Gastrointestinal Peptides as Therapeutic Targets to Mitigate Obesity and Metabolic Syndrome
Sign Up to like & getrecommendations! Published in 2020 at "Current Diabetes Reports"
DOI: 10.1007/s11892-020-01309-9
Abstract: Purpose of Review Obesity affects over than 600 million adults worldwide resulting in multi-organ complications and major socioeconomic impact. The purpose of this review is to summarise the physiological effects as well as the therapeutic… read more here.
Keywords: glp; therapeutic targets; peptides therapeutic; gastrointestinal peptides ... See more keywords
The effects of glucagon-like peptide type 1 (GLP-1) and its analogues in adipose tissue: is there a way to thermogenesis?
Sign Up to like & getrecommendations! Published in 2020 at "Current molecular medicine"
DOI: 10.2174/1566524020666201201095029
Abstract: Obesity is a global problem and the most common metabolic disorder leading to many associated diseases, such as arterial hypertensi on, ischemic heart disease, type 2 diabetes, certain types of cancer, impaired lipid and uric… read more here.
Keywords: glucagon like; glp; adipose tissue; type ... See more keywords
Therapy of obesity in women with PCOS using GLP-1 analogues - benefits and limitations [Terapia otyłości u kobiet z PCOS przy zastosowaniu analogów GLP-1 - korzyści i ograniczenia].
Sign Up to like & getrecommendations! Published in 2022 at "Endokrynologia Polska"
DOI: 10.5603/ep.a2022.0047
Abstract: Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine disorder among women of reproductive age. The incidence ranges from approx. 6% to 20%. PCOS is characterized by a spectrum of symptoms and clinical features that includes… read more here.
Keywords: glp; therapy; pcos; obesity ... See more keywords